Edition:
United States

Organovo Holdings Inc (ONVO.OQ)

ONVO.OQ on NASDAQ Stock Exchange Global Market

1.13USD
23 Apr 2018
Change (% chg)

$-0.05 (-4.24%)
Prev Close
$1.18
Open
$1.19
Day's High
$1.19
Day's Low
$1.10
Volume
177,755
Avg. Vol
235,180
52-wk High
$3.19
52-wk Low
$0.91

Select another date:

Mon, Mar 26 2018

BRIEF-Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement

* ORGANOVO DIVISION SAMSARA SCIENCES ANNOUNCES MULTI-YEAR SUPPLY AGREEMENT WITH LONZA BIOSCIENCE SOLUTIONS

BRIEF-Organovo Holdings- Entered Sales Agreement Where Co May Offer, Sell Shares In 'At Market' Sales Transactions With Offering Price Of Up To $50 Million

* ORGANOVO HOLDINGS- ENTERED SALES AGREEMENT WHERE CO MAY OFFER, SELL SHARES IN 'AT MARKET' SALES TRANSACTIONS WITH OFFERING PRICE OF UP TO $50 MILLION

BRIEF-Organovo Holdings Files For Mixed Shelf Offering Of Up To $100 Mln

* ORGANOVO HOLDINGS INC FILES FOR MIXED SHELF OFFERING OF UP TO $100 MILLION - SEC FILING Source text (http://bit.ly/2EQ7FuR) Further company coverage:

BRIEF-Organovo Reports Q3 Loss Per Share Of $0.07

* ORGANOVO ANNOUNCES FISCAL THIRD-QUARTER 2018 RESULTS; COMPANY UPDATES FULL-YEAR FISCAL 2018 OUTLOOK

BRIEF-Organovo Receives Orphan Designation From U.S. FDA For 3D Bioprinted Therapeutic Liver Tissue

* ORGANOVO RECEIVES ORPHAN DESIGNATION FROM U.S. FDA FOR 3D BIOPRINTED THERAPEUTIC LIVER TISSUE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY Source text for Eikon: Further company coverage:

BRIEF-Organovo posts Q3 loss per share $0.09

* Organovo announces fiscal second-quarter 2018 results; company shifts commercial focus to higher-value disease modeling opportunities and updates full-year fiscal 2018 outlook

BRIEF-Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease

* Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease

Select another date: